With 60 percent ownership, Caribou Biosciences, Inc. boasts of strong institutional backing
| CRBU Stock | USD 1.64 0.08 4.65% |
Slightly above 61% of Caribou Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Caribou Biosciences suggests that many traders are alarmed. Caribou Biosciences' investing sentiment can be driven by a variety of factors including economic data, Caribou Biosciences' earnings reports, geopolitical events, and overall market trends.
Caribou |
Key Insights Given the large stake in the stock by institutions, Caribou Biosciences stock price might be vulnerable...
Read at finance.yahoo.com
 |
Caribou Biosciences Fundamental Analysis
We analyze Caribou Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Caribou Biosciences is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Caribou Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Caribou Biosciences stock to make a market-neutral strategy. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics with similar companies.
Peers
Caribou Biosciences Related Equities
| BEAM | Beam Therapeutics | 1.53 |
| ||
| ADPT | Adaptive Biotechnologies | 2.84 |
| ||
| CRSP | Crispr Therapeutics | 3.88 |
| ||
| EDIT | Editas Medicine | 5.97 |
| ||
| PRME | Prime Medicine, | 6.67 |
| ||
| VERV | Verve Therapeutics | 7.99 |
| ||
| FATE | Fate Therapeutics | 11.98 |
| ||
| SANA | Sana Biotechnology | 14.88 |
| ||
| NTLA | Intellia Therapeutics | 15.14 |
|
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.